asthma
The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns
March 10, 2020Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology
The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
Novartis abandons asthma drug after Phase 3 trial results
December 17, 2019Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d
Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma
August 2, 2019Medical Communications, Sales and Marketing Europe, GSK, Nucala, asthma, pharma
Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, …
Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma
May 30, 2019Research and Development Novartis, QVM149, asthma, pharma
Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …
Sanofi’s Dupixent approved in Europe for severe asthma maintenance
May 9, 2019Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma
Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …
Traffic pollution linked to four million childhood asthma cases each year
April 11, 2019Research and Development Air pollution, NO2, Traffic, asthma, emissions, pollution, public health
Air pollution is linked to four million cases of childhood asthma each year, according to research published in The Lancet …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
First asthma pill in two decades could treat condition by reducing airway muscle
February 14, 2019Research and Development asthma, pharma
Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …
Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler
January 31, 2019Sales and Marketing Advair, COPD, FDA, Wixela, asthma, generic, pharma
Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to …
NICE recommends AstraZeneca’s Fasenra as third treatment option for severe asthma
January 4, 2019Medical Communications, Sales and Marketing AstraZeneca, Fasenra, NHS, NICE, UK, asthma, pharma
It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s …
Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling
November 27, 2018Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …
AstraZeneca sells off three drugs in deal worth $350 million
November 6, 2018Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties
Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …
More woes for Teva as two late-stage asthma studies bomb
January 23, 2018Manufacturing and Production, Research and Development Teva, asthma, pharma
In yet more bad news for Teva, it has emerged that two of the firm’s late-stage studies in asthma have …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
